Caffeinated and decaffeinated coffee effects on plasma lipoprotein cholesterol, apolipoproteins, and lipase activity: a controlled, randomized trial.
Coffee consumption has been associated with elevated plasma cholesterol. One hundred eighty-one men consumed a standard caffeinated coffee for 2 mo followed by randomization to continue caffeinated coffee (control), change to decaffeinated coffee or no coffee for 2 mo. Plasma low-density-lipoprotein (LDL) cholesterol and apolipoprotein B concentrations increased significantly (0.12 +/- 0.65 mmol/L, P less than 0.025; 0.06 +/- 0.12 g/L, P less than 0.0004, respectively) in the group that changed to decaffeinated coffee. In a subgroup (n = 51), post-heparin lipoprotein lipase decreased significantly more (-270 mmol free fatty acids.L-1.h-1, P less than 0.003) in the decaffeinated-coffee group. Resting heart rate and blood pressure did not change significantly. Change from caffeinated to decaffeinated coffee increased plasma LDL cholesterol and apolipoprotein B whereas discontinuation of caffeinated coffee revealed no change. This finding suggests that a coffee component other than caffeine is responsible for the LDL cholesterol, apolipoprotein B, and lipase activity changes reported in this investigation.
Superko
H R
HR
Stanford Center for Research in Disease Prevention, Stanford University School of Medicine, CA.
Bortz
W
W
Williams
P T
PT
Albers
J J
JJ
Wood
P D
PD
D000328:Adult; D001053:Apolipoproteins / Q000097:blood*; D002110:Caffeine / Q000494:pharmacology*; D002784:Cholesterol / Q000097:blood*; D003069:Coffee; D006801:Humans; D008049:Lipase / Q000097:blood*; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009994:Osmolar Concentration; D012016:Reference Values
D001053:Apolipoproteins; D003069:Coffee; D008074:Lipoproteins; C030104:lipoprotein cholesterol; D002110:Caffeine; D002784:Cholesterol; D008049:Lipase